Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

ur ability to successfully implement our in-licensing and acquisition strategy; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by the government; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales; a determination by a regulatory agency that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; the loss of branded product exclusivity periods and related intellectual property; and exposure to securities that are subject to market risk including auction-rate securities the market for which is currently illiquid; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo Pharmaceuticals


SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... HILL, N.C. , July 2, 2015  New ... Because of its leading role in educating thought leaders ... functions that can heavily influence how well a new ... a new study from research and consulting leader Best ... Affairs leaders need to focus on are early stage ...
(Date:7/2/2015)... NEW YORK , July 2, 2015 /PRNewswire/ ... of a conspicuously high-growth market segment in hematology ... research publisher said that Roche,s recent unveiling of its ... into the cobas m 511 hematology ... not only capture growth enjoyed by current leader ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... Dec. 27, 2010 King Pharmaceuticals®, Inc. (NYSE: ... PTIE ) today announced that King has resubmitted a ... Food and Drug Administration (FDA) in response to a Complete ... is a Class 2 resubmission with a six month review ...
... Cepheid (Nasdaq: CPHD ) today announced ... investor conference, and invited investors to participate via webcast.J. ... a.m. Pacific TimeTo access the live webcast for this ... at least 15 minutes before the scheduled start time ...
Cached Medicine Technology:King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY® 2King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY® 3Cepheid to Webcast Upcoming Financial Presentation 2
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... the solar industry’s leading recognition of technical sales expertise from the North American ... Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established national ...
(Date:7/3/2015)... ... 03, 2015 , ... Scientists at several top US cancer centers believe they ... exposure. Click here to read the complete story , just posted on the ... Sinai Medical Center, and New York University exposed mice with a mutation on the ...
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the ... good blender and easily accessible, quality ingredients. Aurora Natural is proud to introduce a ... added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering a ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt ... in 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... fatigue is often a major problem for cancer ... completing therapy. Researchers at Mayo Clinic ( http://www.mayoclinic.org/oncology-rst/ ... ( http://ncctg.mayo.edu/ ) (NCCTG) recently completed a study ... and found that, while it did not improve ...
... M.D., Ph.D., FASTRO, and William McBride, D.Sc., Ph.D., have ... Oncology,s most prestigious award, the Gold Medal. They will ... during ASTRO,s 52nd Annual Meeting, taking place October 31 ... Medal is bestowed on revered members who have made ...
... ... targeted internet traffic to their websites. The solution is all in the PT Marketing Academy. ... to use WordPress blogs, search engine optimization for Google search, Facebook, Twitter, YouTube, and all ... ...
... Montreal, Quebec June 2, 2010 Baby boomers retiring ... in Canada or the U.S., however, a study suggests retirees ... and from the mainstream of Mexican life. The study, ... presented at the 2010 Congress for the Humanities and Social ...
... current problem is the mission of analytical chemistry, according to ... the University of the Basque Country (UPV/EHU). The group,s name ... these problems - Farmartem: the abbreviation in Spanish of pharmaceuticals, ... Art has been the line of research least worked on ...
... after mastectomy fared better, researchers say , WEDNESDAY, June ... after a mastectomy may influence the odds of breast ... the Catholic University of Louvain (Leuven) in Belgium looked ... in 327 women from one to four years after ...
Cached Medicine News:Health News:Results from a study testing methylphenidate for cancer-related fatigue 2Health News:Results from a study testing methylphenidate for cancer-related fatigue 3Health News:Larson, McBride named 2010 ASTRO Gold Medalists 2Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 2Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 3Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 4Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 5Health News:Retirees in Mexico cut off, study says 2Health News:Basque researchers apply chemistry to restoration of paintings and dating of signatures 2Health News:Basque researchers apply chemistry to restoration of paintings and dating of signatures 3
151 channels cover the entire head with a high density, with provisions for the eyes and ears. Patients and subjects are examined in a comfortable seated position or laying down....
... is achieved using an increased tilt angle ... patient bed. The patient preparation can be ... case of an emergency the patient can ... for e.g. resuscitation purposes. The integrated neck ...
... be used for demonstration and training in: ... , ,The Model Practice Eye is ... the human eye size and shape and the ... lens and pupil arrangement simulate the optics of ...
... Canons DR innovations, the CXDI-31 is the ... compact and lightweight design, the Canon CXDI-31 ... screen-film cassettes. It is designed to capture ... get with fixed devices and supports lateral ...
Medicine Products: